Insider Alert: Omada Health CEO Sean Duffy Sells 31,457 Shares
Key Points
Traded 31,457 shares with a transaction value of ~$735,150 based on a weighted average price of $23.37 per share.
The activity involved shares equal to 2% of the total equity stake held before the filing, including direct transactions equal to 8% of the prior direct position.
The transaction included the exercise of 21,572 options at $9.18 per share, followed by an immediate sale, with Duffy maintaining ~852,000 shares held indirectly through family trusts.
Dispositions were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, representing routine equity management as of the Sept. 1, 2026, transaction date.
Chief Executive Officer Sean P. Duffy reported the disposition of 31,457 shares of Omada Health, Inc. (NASDAQ:OMDA) on Sept. 1, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | ~$735,150 |
| Shares sold | 31,457 |
| Post-transaction shares (directly held) | 401,976 |
| Post-transaction shares (indirectly held) | 851,659 |
| Post-transaction value | $28.63 million |
Transaction value based on SEC Form 4 weighted average sale price ($23.37); post-transaction value based on Sept. 01, 2026, market close ($22.84).
Key questions
- What was the breakdown between open-market and tax-related transactions?
Duffy sold 21,572 shares in the open market and used 9,885 shares to satisfy tax withholding obligations associated with the vesting of equity awards. - What role did the Rule 10b5-1 plan play in these sales?
The entire transaction was executed under a trading plan established on March 13, 2026, which allows insiders to schedule trades in advance to avoid concerns regarding material non-public information. - How does the current equity position compare to the derivative holdings?
In addition to the ~1.3 million shares of common stock held directly and through family trusts, Duffy holds 512,994 options outstanding, including vested and unvested awards. - How has the stock performed leading up to this transaction?
As of the Sept. 1, 2026 transaction date, the company recorded a one-year total return of (4%), with shares priced at $23.31 at the Sept. 2, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-08) | $22.18 |
| Market Capitalization | $1.39 billion |
| Revenue (TTM) | $309.80 million |
| Net Income (TTM) | $4.30 million |
Company Snapshot
- Omada Health delivers a comprehensive suite of virtual care programs focused on cardiometabolic health, musculoskeletal conditions, behavioral health, and weight management, generating revenue through employer and health plan partnerships.
- The company operates a digital-first care delivery model that combines behavioral coaching, clinical support, and personalized interventions to address chronic disease management and prevention across its service offerings.
- Omada's primary customers include large employers, health insurance plans, and health systems seeking to improve population health outcomes and reduce healthcare expenditures through preventive and chronic disease management solutions.
Omada Health is a leading digital health platform with a market capitalization of $1.30 billion, serving as a critical infrastructure provider in the virtual care and population health management space. The company has achieved profitability on a TTM basis with $309.80 million in revenue, demonstrating the commercial viability of its integrated care delivery model. Omada's competitive advantage derives from its evidence-based clinical protocols, proprietary behavioral health technology, and established relationships with major health plans and employer groups across the United States.
What this transaction means for investors
CEO Duffy's sale isn't something that should scare prospective investors away from buying Omada Health shares. They are part of a preplanned trading program, as opposed to Duffy making any type of "bet" on where OMDA stock may be heading. Furthermore, CEO Duffy still holds $29 million in shares, so this $700,000 sale isn't really a big deal by comparison; it's just basic liquidity for a C-suite insider. Another thing worth noting is that Duffy will be departing the CEO role on Jan. 1, 2027, and becoming Executive Chair.
As for Omada Health's actual business, the company remains an intriguing "between-visits" healthcare leader, helping over one million members with weight health, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Patients using Omada's solutions have better outcomes than those without, helping the company carve out a leadership position in the niche.
Omada also helps GLP-1 users maintain muscle while reducing body fat and weight at a faster rate. The company also helps patients who are done with GLP-1 treatments avoid putting back on as much weight as is typically seen among users who quit cold turkey, showing that life after GLP-1 may actually be possible. Omada trades at a lofty 51 times earnings, but it just grew sales and member count by 43% and 45% in its last quarter, while adjusted EBITDA margins rose from -0.3% to 12.3%. I'll be keeping OMDA stock on my shortlist, especially if it keeps racking up studies highlighting its success.
Josh Kohn-Lindquist has positions in Omada Health. The Motley Fool has positions in and recommends Omada Health. The Motley Fool has a disclosure policy.